Emergent BioSolutions (EBS) Stock Forecast & Price Target

Emergent BioSolutions is benefiting from a clearer financial and operational setup, as the $75 million repurchase of 3.875% senior unsecured notes reduced outstanding principal to about $364.7 million and helped bring total debt to roughly $515 million, with a blended interest rate near 5.6%. Its liquidity also appears solid, with expected cash and cash equivalents above $180 million by 3Q26 plus access to an additional $50 million revolver, while the planned refinancing of 2028 notes could further improve the capital structure. Fundamentally, the outlook is supported by recurring government demand—such as the ~$24 million BARDA CYFENDUS modification and the $21.5 million BioThrax order—alongside commercial momentum from NARCAN and ACAM2000 and restructuring savings of about $40 million annually.

Emergent BioSolutions is facing a deteriorating core franchise as NARCAN sales fell 22% in 2Q26 and full-year 2026 revenue guidance was cut to $645-$675M from $720-$760M, reflecting accelerating erosion from new OTC naloxone competition and unfavorable U.S. price-volume mix. Although MCM products such as BioThrax and ACAM2000 benefited from timing and international sales, these revenues remain lumpy and dependent on government purchase options, funding, and procurement cycles, limiting visibility and durability. The DCF profile also signals weak fundamentals, with an enterprise value of about $872M to $1.1B and a $600M firm value after projected mid-2027 cash and debt, while key risks include contract shortfalls, approval setbacks, and dilution risk.